CareDx shares have doubled in 2026. Will July 30 earnings support the surge?
CareDx reports Q2 results on July 30 as investors assess transplant testing growth, Medicare coverage clarity and the Naveris strategy.
Medical Devices & Diagnostics
Pharma & Biotech
Why Naveris’s NavDx performance outcomes could alter HPV cancer follow‑up standards
See how Naveris’s NavDx ctHPV DNA results are reshaping HPV cancer surveillance and what this means for clinicians, payers, and precision oncology adoption.